Regulatory Context for Plastic Surgery

Plastic surgery in the United States operates within a layered framework of federal and state oversight that governs practitioner licensing, facility accreditation, device approval, and patient safety standards. This page maps the primary regulatory instruments, enforcement mechanisms, and compliance obligations that apply to plastic surgery practices and the facilities in which procedures are performed. Understanding this framework is essential for evaluating whether a provider or facility meets the baseline legal and professional standards established by named public authorities. The National Plastic Surgery Authority index provides broader orientation across the field.

Enforcement and Review Paths

Regulatory enforcement in plastic surgery flows through at least three distinct channels: federal agency action, state medical board oversight, and accrediting body review.

The U.S. Food and Drug Administration (FDA) holds authority over medical devices used in plastic surgery, including breast implants, tissue expanders, and injectable fillers. Under 21 CFR Part 880 and related subparts, FDA classifies these devices and can issue warning letters, recall notices, or market withdrawal orders when safety standards are not met. The FDA's 2019 Breast Implant Safety Action, which led to the market withdrawal of Allergan's BIOCELL textured breast implants following linkage to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), illustrates the enforcement reach of this pathway.

State medical boards exercise primary jurisdiction over physician licensure and conduct. Each state board operates under its own enabling statute — for example, California's Medical Practice Act (Business and Professions Code §2000 et seq.) — and has authority to investigate complaints, impose conditions on licenses, suspend practitioners, or revoke licensure entirely. Board actions are reportable to the National Practitioner Data Bank (NPDB), a federal repository administered by the Health Resources and Services Administration (HRSA) under 45 CFR Part 60.

Accrediting organizations such as The Joint Commission, the American Association for Accreditation of Ambulatory Surgery Facilities (AAAASF), and the Accreditation Association for Ambulatory Health Care (AAAHC) conduct facility-level reviews. Loss of accreditation status can trigger payer contract termination and, in states requiring accreditation for outpatient surgical facilities, operational closure.

Primary Regulatory Instruments

Four categories of regulatory instrument shape plastic surgery practice in the United States:

Federal device regulation — FDA premarket approval (PMA) requirements under 21 U.S.C. §360e for Class III devices, including silicone gel-filled breast implants. FDA's guidance document Breast Implants - Certain Labeling Recommendations to Improve Patient Communication (2020) establishes informed consent requirements specific to implant procedures.
State licensure law — Physician licensure statutes in all 50 states, plus District of Columbia, require active licensure in the state of practice. Specialty board certification (e.g., from the American Board of Plastic Surgery) is not legally mandated at the federal level but is required by many hospitals and insurers for credentialing.
Facility certification and Medicare conditions of participation — Ambulatory surgical centers (ASCs) that participate in Medicare must comply with the Conditions for Coverage at 42 CFR Part 416, administered by the Centers for Medicare and Medicaid Services (CMS).
Controlled substance and pharmacy regulation — The Drug Enforcement Administration (DEA) governs anesthesia-related controlled substances under the Controlled Substances Act (21 U.S.C. §801 et seq.), applicable to surgical settings where general or sedation anesthesia is used.

Compliance Obligations

Practices performing plastic surgery face overlapping compliance obligations across federal, state, and accreditation frameworks. Key structural obligations include:

Informed consent documentation consistent with both state law requirements and, for FDA-regulated devices, device-specific labeling guidance. The FDA's 2021 Boxed Warning requirement for all breast implants mandates that patients receive and sign a standardized checklist before implant placement.
Adverse event reporting under the FDA's MedWatch program (21 CFR Part 803) for device-related incidents resulting in serious injury or death. Facilities operating as device user facilities carry mandatory reporting obligations with 30-day and 5-day reporting windows depending on event severity.
HIPAA compliance under 45 CFR Parts 160 and 164 (administered by the HHS Office for Civil Rights), governing protected health information across all patient communications, records, and billing functions. Civil monetary penalties can reach $1.9 million per violation category per calendar year (HHS OCR Civil Money Penalties).
Credentialing and privileging at hospital-affiliated or ASC settings, governed by CMS Conditions of Participation at 42 CFR §482.22 for hospitals.

Exemptions and Carve-Outs

Not all plastic surgery-adjacent procedures fall under the same regulatory burden. Several structural carve-outs define the boundaries of oversight:

Office-based surgery performed entirely outside a licensed ASC or hospital may fall outside CMS's Conditions for Coverage if the facility does not bill Medicare. However, 34 states have enacted office-based surgery regulations that impose independent accreditation or inspection requirements even in non-Medicare settings, according to the American Society of Plastic Surgeons' regulatory tracking resources.

Cosmetic-only procedures without any reconstructive component are generally excluded from insurance mandates under the Affordable Care Act's essential health benefits framework, though reconstructive surgery following mastectomy is separately protected under the Women's Health and Cancer Rights Act of 1998 (29 U.S.C. §1185b).

Research and investigational use of unapproved devices or techniques may qualify for exemption from standard PMA pathways under FDA's Investigational Device Exemption (IDE) regulations at 21 CFR Part 812, subject to Institutional Review Board (IRB) approval and FDA oversight.

The boundary between cosmetic and reconstructive surgery also has direct compliance implications: procedures coded and billed as reconstructive must meet payer-specific medical necessity criteria, and miscoding carries False Claims Act exposure under 31 U.S.C. §3729. Detailed safety-related considerations are addressed on the safety context and risk boundaries for plastic surgery page.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)